Version June 2024
| EORTC studies | ||||
| Study | Response (percent) | MST (months) | ||
| Mitoxantrone | 2.4 | 7.5 | ||
| Epidoxorubicin | 13.5 | 8.9 | ||
| Etoposide (IV) | 4.2 | 6.7 | ||
| Etoposide (PO) | 7.3 | 8.7 | ||
| Paclitaxel | 0 | 9.3 | ||
| Poor prognostic factors in multivariate analysis | ||||
| | Variable | MST (months) | ||
| Performance status (PS) | Good (0) | 10.7 | ||
| Poor (1-2) | 7.2 | |||
| WBC count | High (>8.3) | 6 | ||
| Low (<8.3) | 10.4 | |||
| Hemoglobin difference* | High (>1 g/dL) | 7.3 | ||
| Low (<1 g/dL) | 9.6 | |||
| Histologic diagnosis | Definite | 9.8 | ||
| Possible | 6 | |||
| Sarcomatous subtype | Present | 5 | ||
| Other subtype | 8.4-9.1 | |||
| EORTC prognostic groups | ||||
| Group characteristics | MST (months) | 1 yr OS | 2 yr OS | |
| Low risk (prognostic score <1.27) | 10.8 | 40 percent | 14 percent | |
| Equivalent to having 0-2 poor prognostic factors | ||||
| High risk (prognostic score >1.27) | 5.5 | 12 percent | 0 percent | |
| Equivalent to having three or more poor prognostic factors | ||||
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
